On Tuesday, the Food and Drug Administration (FDA) approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common ...

The Food and Drug Administration approved Johnson & Johnson's nasal spray to be used alone in adults ... new major depression treatment to win FDA approval in more than three decades.

The FDA has approved Neffy, a needle-free nasal spray, for children aged 4 and up, providing fast and effective treatment for ...

Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy ... two oral antidepressants. The FDA in 2019 approved Spravato, a close ...

The FDA has approved neffy 1 mg epinephrine nasal spray for treating anaphylaxis and other type 1 allergic reactions in ...

Neffy 1 mg is now approved by the FDA to treat pediatric patients who weigh 33 to 65 lbs. Neffy was first FDA-approved as a 2 ...

Milestone Pharmaceuticals Inc. announced that the FDA has ... for its nasal spray CARDAMYST™ (etripamil), aimed at treating Paroxysmal Supraventricular Tachycardia (PSVT). If approved, Milestone ...

Neffy 1 mg is the “first significant innovation” for epinephrine delivery in small children aged 4 years and up in over 35 ...

FDA approves Neffy 1 mg for children aged 4+ weighing 15 to <30 kg for allergic reactions. Most insured patients can access Neffy for $25, while cash price is $199 for two doses. Our government tr ...